Sixty three recipients of an artificial hip implant manufactured by a Johnson & Johnson subsidiary have filed suit in Israeli court, claiming that the devices broke down and caused them pain and a high level of metal ions in their blood.
According to a report in Jewish Business News, the plaintiffs “describe attendant problems in functioning accompanied by infections, tumors, fractures ...
continue reading...
A piece in the New York Times on Johnson & Johnson’s new corporate branding campaign says the company urgently needed to distance itself from the “bad press of product recalls and pending litigation,” of which it experienced much lately.
In 2010, the story points out, Johnson & Johnson’s McNeil Consumer Healthcare unit recalled more than 280 million packages of over-the-counter medications including Motrin, children’s Tylenol liquid and Benadryl.
Also in 2010, the ...
continue reading...
More than 170 residents of South Africa are filing suit against Johnson & Johnson subsidiary DePuy Orthopedics over problems with the company’s all-metal hip implants, according to a story on IOL News.
The story says the South African plaintiffs are suing in a court in England — where the implants in question were manufactured — because they were unable to sue in their home country. They’re seeking millions of dollars over ...
continue reading...Although Johnson & Johnson’s overall profit fell 10.6 percent to $3.5 billion in the first quarter of 2013, over-the-counter sales through the company’s consumer division are up 14 percent in the United States, according to a story in the Philadelphia Inquirer.
The company is putting more Tylenol and Motrin on stores shelves through its McNeil Consumer Healthcare Unit, located outside Philadelphia. Although McNeil also has plants in Lancaster, Pa., and in ...
continue reading...
An investing blog on CNBC.com warns potential investors about health care giant Johnson & Johnson.
The stock is already up more than 22 percent on the year, the blog entry says, and trading at a price/earnings ratio more than twice that of rival Abbott Laboratories. But the entry points out that investors are worried about the company’s prospects for organic growth, especially in light of its reputation still being in “recovery” ...
continue reading...
According to a story in the International Business Times, a batch of baby powder from a Johnson & Johnson plant in India was found to be contaminated with a carcinogen. That finding prompted the Food and Drug Administration to cancel Johnson & Johnson’s license to manufacture the powder at that plant.
In recent years, Johnson & Johnson has been obliged to recall nearly 300 million packages of over-the-counter medications, including Motrin, ...
continue reading...
